✦ LIBER ✦

Sex-specific outcomes following revascularization with zotarolimus-eluting stents: Comparison of angiographic and late-term clinical results

✍ Scribed by Ryan A. Brown; Marcus Williams; Colin M. Barker; Laura Mauri; Ian T. Meredith; Jean Fajadet; William Wijns; Martin B. Leon; David E. Kandzari

Book ID: 101824356
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 134 KB
Volume: 76
Category: Article
ISSN: 1522-1946
DOI: 10.1002/ccd.22624

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB